Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$62.61 ▲ +1.15
(+1.87%)
MKT CAP: $9.85B • VOL: 2.01M
52W L $40 52W H $91
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$53
MEDIAN
$70
MEAN
$71
HIGH
$85
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PCVX TAPE
PCVX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $75.76 | $72.00 | 2025-02-14 | $56.98 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $78.89 | $73.88 | 2025-02-06 | $58.85 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $71.38 | $68.87 | 2025-01-29 | $60.11 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $63.86 | — | 2025-01-17 | $61.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $55.10 | $59.48 | 2025-01-09 | $55.72 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $74.51 | $65.11 | 2024-12-18 | $54.47 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $60.73 | $63.24 | 2024-12-04 | $58.23 | -4.3% | 48% | C |